Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $91.00 at Chardan Capital

Intellia Therapeutics (NASDAQ:NTLA - Free Report) had its price target raised by Chardan Capital from $88.00 to $91.00 in a report published on Monday,Benzinga reports. They currently have a buy rating on the stock.

NTLA has been the subject of several other research reports. Robert W. Baird lowered their price target on shares of Intellia Therapeutics from $24.00 to $18.00 and set a "neutral" rating for the company in a research report on Friday, October 25th. Royal Bank of Canada reissued an "outperform" rating and set a $54.00 target price on shares of Intellia Therapeutics in a research report on Thursday, September 19th. The Goldman Sachs Group decreased their target price on shares of Intellia Therapeutics from $31.00 to $20.00 and set a "neutral" rating for the company in a research report on Friday, October 25th. Stifel Nicolaus decreased their target price on shares of Intellia Therapeutics from $80.00 to $64.00 and set a "buy" rating for the company in a research report on Wednesday, September 11th. Finally, Oppenheimer decreased their target price on shares of Intellia Therapeutics from $70.00 to $60.00 and set an "outperform" rating for the company in a research report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Intellia Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $53.88.

Intellia Therapeutics Price Performance

Shares of Intellia Therapeutics stock traded up $0.20 during trading hours on Monday, reaching $14.17. The company's stock had a trading volume of 5,612,627 shares, compared to its average volume of 1,699,631. The stock has a market cap of $1.44 billion, a P/E ratio of -2.58 and a beta of 1.81. Intellia Therapeutics has a one year low of $13.54 and a one year high of $34.87. The firm has a 50 day moving average price of $18.64 and a 200-day moving average price of $22.04.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. The business's revenue for the quarter was down 24.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.38) earnings per share. As a group, sell-side analysts forecast that Intellia Therapeutics will post -5.13 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CAO Michael P. Dube sold 2,012 shares of the business's stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the sale, the chief accounting officer now owns 47,012 shares in the company, valued at approximately $893,698.12. The trade was a 4.10 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 3.20% of the stock is owned by insiders.

Institutional Trading of Intellia Therapeutics

Institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new position in shares of Intellia Therapeutics in the 1st quarter valued at $160,000. Swiss National Bank increased its holdings in shares of Intellia Therapeutics by 1.3% in the 1st quarter. Swiss National Bank now owns 167,900 shares of the company's stock valued at $4,619,000 after acquiring an additional 2,200 shares during the period. ProShare Advisors LLC increased its holdings in shares of Intellia Therapeutics by 11.9% in the 1st quarter. ProShare Advisors LLC now owns 23,235 shares of the company's stock valued at $639,000 after acquiring an additional 2,466 shares during the period. Vanguard Group Inc. increased its holdings in shares of Intellia Therapeutics by 8.9% in the 1st quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company's stock valued at $250,168,000 after acquiring an additional 746,263 shares during the period. Finally, EntryPoint Capital LLC increased its holdings in shares of Intellia Therapeutics by 61.1% in the 1st quarter. EntryPoint Capital LLC now owns 4,122 shares of the company's stock valued at $113,000 after acquiring an additional 1,563 shares during the period. Hedge funds and other institutional investors own 88.77% of the company's stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.